Solitary fibrous tumor of thoracic cavity, extra-thoracic sites and central nervous system: Clinicopathologic features and association with local recurrence and metastasis
Introduction
Solitary fibrous tumor (SFT) is a mesenchymal neoplasm of fibroblastic type, encompassing a histological spectrum with two main morphological variants: the SFT phenotype characterized by a so-called patternless architecture or short fascicular pattern, with alternating hypocellular and hypercellular areas with thick bands of collagen, and the hemangiopericytoma (HPC) phenotype characterized by high cellularity and a delicate, rich network of reticulin fibers typically investing individual cells [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44]. Thin-walled, branching vessels, called HPC-like or staghorn vessels, are a feature shared by both phenotypes. The discovery of a shared, recurrent NAB2-STAT6 gene arrangement in both SFT and HPC has confirmed the identical nature of these neoplasms [1], [2], [3], [17], [18], [19], [21], [32], [42]. SFTs may occur at any anatomical site, including pleural cavities, extremities, head and neck, abdominal cavity, pelvis, retroperitoneal space, visceral organs, bone, and central nervous system (CNS) [1], [2], [3]. Predicting the clinical behavior of SFT has long been a notoriously difficult task for both oncologists and pathologists [4]. The current 2016 WHO CNS grading scheme incorporates phenotype (SFT and HPC) and mitotic rate to stratify tumors into three groups (grade I, II, and III), while thoracic and extrathoracic tumors were classified by mitotic rate alone into SFT and malignant SFT according to the 2013 WHO classification for soft tissue tumors [1], [2], [5], [6], [7], [10], [14], [32]. However, it is well established that morphologically benign tumors may occasionally metastasize and conversely that many tumors, classified as malignant based on histologic findings, have an indolent clinical course [8], [9]. The development of risk models for the prediction of metastatic risk in SFTs has resulted in improved prognostication over the traditional benign/malignant dichotomy, and these models are recommended by the 2019 WHO classification of soft tissue tumors [1], [3], [4], [6], [10], [11], [12], [13], [14], [15], [45], [46], [47]. However, neither of these models have been validated for CNS SFT/HPC, nor have they been tested regarding their association with local recurrence in non-CNS sites. The aim of this study is to investigate the prognostic value of the published three- and four-variable risk stratification models by Demicco et al. [10], [11] for both local recurrence and distant metastasis in thoracic, extrathoracic, and CNS SFT in order to establish a unified risk assessment approach for these neoplasms.
Section snippets
Material and methods
The present study was approved by the Institutional Review Board of Northwestern Memorial Hospital.
Clinical characteristics
Data on anatomic location, age at presentation and gender are summarized in Table 1. SFTs occurred predominantly in females (54%, female to male ratio 1.2:1), with a median age of 56 years for females and 57 years for males. Tumors were located in the CNS (N = 17), thoracic cavity (N = 28), and extrathoracic sites (N = 27) (Fig. 1A). Patients with thoracic and extrathoracic SFT usually presented with a slowly enlarging mass of variable duration. In most cases of CNS tumors, the symptoms were
Discussion
To the best of our knowledge, our study is the first to test the performance of the published three- and four-variable risk stratification models by Demicco et al. [10], [11] for risk stratification of local recurrence in addition to distant metastasis, as well as to assess the performance of these models relative to WHO grading criteria for SFT/HPC in the CNS.
In this study, with regard to histologic appearances, CNS tumors were not perceptibly different from SFTs arising in the thoracic cavity
Conclusion
In this study, we show that for non-CNS tumors, both the three and four-variable risk stratification models by Demicco et al. [10], [11] and mitotic activity were significantly associated with metastasis-free and recurrence-free survival. By contrast, in CNS cases, no significant differences were seen in either metastasis-free or recurrence-free survival based on either the three- or four-variable risk models. Though none of the differences were significant, overall, WHO grade appears to be the
Funding
No external funds were obtained for this work.
CRediT authorship contribution statement
All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. We certify that this manuscript is not under consideration elsewhere.
Conflict of interest
We declare that we have no conflict of interest.
References (51)
- et al.
Hemangiopericytoma. An analysis of 106 cases
Hum. Pathol.
(1976) - et al.
Clinical outcomes of extra-thoracic solitary fibrous tumours
Eur. J. Surg. Oncol.
(2009) - et al.
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model
Mod. Pathol.
(2012) - et al.
Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model
Mod. Pathol.
(2017) - et al.
Extrapleural solitary fibrous tumor: a distinct entity from pleural solitary fibrous tumor. An update on clinical, molecular and diagnostic features
Ann. Diagn. Pathol.
(2018) - et al.
TERT promoter mutations and prognosis in solitary fibrous tumor
Mod. Pathol.
(2016) - et al.
Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites
Hum. Pathol.
(1995) - et al.
Solitary fibrous tumor with neuroendocrine and squamous dedifferentiation: a potential diagnostic pitfall
Hum. Pathol.
(2018) - et al.
Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential
Hum. Pathol.
(2015) - et al.
Primary intracranial haemangiopericytoma: comparison of survival outcomes and metastatic potential in WHO grade II and III variants
J. Clin. Neurosci.
(2014)
Resectable extra-pleural and extra-meningeal solitary fibrous tumours: a multi-centre prognostic study
Eur. J. Surg. Oncol.
Solitary fibrous tumor
Solitary fibrous tumor
Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients
Brain Pathol.
Predicting behavior of solitary fibrous tumor: are we getting closer to more accurate risk assessment?
Ann. Surg. Oncol.
Extrathoracic location and “borderline” histology are associated with recurrence of solitary fibrous tumors after surgical resection
Ann. Surg. Oncol.
Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases
Am. J. Surg. Pathol.
Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors
Am. J. Surg. Pathol.
Prognosis of solitary fibrous tumors: a multicenter study
Ann. Surg. Oncol.
Clinicopathologic correlates of solitary fibrous tumors
Cancer
Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database
Ann. Oncol.
Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease
J. Neurooncol.
Solitary fibrous tumor: an evolving and unifying entity with unsettled issues
Histol. Histopathol.
Differential diagnosis of solitary fibrous tumors: a study of 454 soft tissue tumors indicating the diagnostic value of nuclear STAT6 relocation and ALDH1 expression combined with in situ proximity ligation assay
Int J. Oncol.
Clinical outcomes of intracranial solitary fibrous tumor and hemangiopericytoma: analysis according to the 2016 WHO classification of central nervous system tumors
J. Neurosurg.
Cited by (5)
Evaluation of Alternative Risk Stratification Systems in a Large Series of Solitary Fibrous Tumors with Molecular Findings and Ki-67 Index Data: Do They Improve Risk Assessment?
2023, International Journal of Molecular SciencesSolitary Fibrous Tumor of the Spine: Imaging Grading Diagnosis and Prognosis
2022, Journal of Computer Assisted Tomography